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Abstract
Background: Patients with diabetic neuropathy (DPN) and fibromyalgia differ substantially in pathogenetic factors
and the spatial distribution of the perceived pain. We questioned whether, despite these obvious differences,
similar abnormal sensory complaints and pain qualities exist in both entities. We hypothesized that similar sensory
symptoms might be associated with similar mechanisms of pain generation. The aims were (1) to compare
epidemiological features and co-morbidities and (2) to identify similarities and differences of sensory symptoms in
both entities.
Methods: The present multi-center study compares epidemiological data and sensory symptoms of a large cohort
of 1434 fibromyalgia patients and 1623 patients with painful diabetic neuropathy. Data acquisition included
standard demographic questions and self-report questionnaires (MOS sleep scale, PHQ-9, PainDETECT). To identify
subgroups of patients with characteristic combinations of symptoms (sensory profiles) a cluster analysis was
performed using all patients in both cohorts.
Results: Significant differences in co-morbidities (depression, sleep disturbance) were found between both disorders.
Patients of both aetiologies chose very similar descriptors to characterize their sensory perceptions. Burning pain,
prickling and touch-evoked allodynia were present in the same frequency. Five subgroups with distinct symptom
profiles could be detected. Two of the subgroups were characteristic for fibromyalgia whereas one profile occurred
predominantly in DPN patients. Two profiles were found frequently in patients of both entities (20-35%).
Conclusions: DPN and fibromyalgia patients experience very similar sensory phenomena. The combination of
sensory symptoms - the sensory profile - is in most cases distinct and almost unique for each one of the two
entities indicating aetiology-specific mechanisms of symptom generation. Beside the unique aetiology-specific
sensory profiles an overlap of sensory profiles can be found in 20-35% of patients of both aetiologies.
Background
Painful diabetic neuropathy (DPN) is a chronic neuro-
pathic pain syndrome caused by a metabolic damage of
primary afferent neurons. Sensory abnormalities predo-
minantly affecting the feet are frequent [1,2]. The sen-
sory symptoms patients suffer from include numbness,
prickling, burning or electric shocks and vary between
the individual patients.
In contrast, fibromyalgia syndrome is a chronic painful
condition which is character i z e db yw i d es p r e a dp a i n
mainly perceived in deep somatic tissues, i.e., in muscles
and joints. The definition is based on the American Col-
lege of Rheumatology (ACR) classification scheme [3].
Fibromyalgia (FM) is also characterized by abnormal
pain sensitivity and frequent additional comorbidities
like sleep disturbances and affective disorders [4]. In
contrast to classic neuropathic pain syndromes the gen-
eral perception of fibromyalgia is that in this disease
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appears to be a subset of patients who additionally suf-
fer from a neurological disease [7,8]
Despite these obvious differences in the disease aetiol-
ogy and the spatial distribution of the pain there are also
striking similarities how the patients express their abnor-
mal sensory perceptions and in particular the quality of
their pain. It is well known that DPN patients frequently
suffer from heat hyperalgesia, which is thought to be a
result of peripheral sensitization of nociceptive afferents,
prickling sensations, burning pain and numbness in the
affected extremities [9]. In fibromyalgia patients a hyper-
sensitivity of the skin to mechanical or thermal stimuli
and burning or prickling sensations as well as pain
attacks have been frequently described [10-12].
Decreased detection thresholds for noxious stimuli like
heat and cold could be demonstrated in quantitative sen-
sory testing [13-15] and there is evidence for enhanced
perception of repetitive nociceptive stimuli, i.e., temporal
and spatial summation [16,17]. The observation of these
phenotypic similarities has led to the hypothesis that
both painful entities might share some similarities in the
underlying pathophysiological mechanisms of pain gen-
eration. In particular central sensitization of afferent
nociceptive processing and attenuation of inhibitory con-
trol systems are pathophysiological mechanisms which
are frequently discussed in the development and mainte-
nance of neuropathic pain syndromes and fibromyalgia.
For these reasons we deliberately used an instrument
which was originally developed and validated to detect
sensory symptoms of neuropathic pain patients, i.e. the
painDETECT questionnaire.
The present investigation was designed to compare
clinical data and sensory symptoms in a large cohort of
1434 fibromyalgia patients and 1623 patients with pain-
ful diabetic neuropathy and was performed in collabora-
tion with the German Research Network on
Neuropathic Pain (DFNS). For future research and bet-
ter treatment options for these diseases it is important
to know which sensory symptoms and pain qualities are
perceived as relevant by the patients themselves. As a
result of this idea “Patient-Reported Outcomes” (PROs)
are already frequently used in clinical research [18].
The specific aims of this study were
(1) to compare epidemiological features and co-mor-
bidities and
(2) to identify similarities and differences of sensory
symptoms and profiles.
Methods
2.1. Study population und data collection
The study was performed at 450 outpatient centers
throughout Germany, including general practitioners,
rheumatologists, orthopaedists, diabetologists, neurolo-
gists and pain specialists. Patients included in the study
were routinely clinically examined within the course of
presenting themselves on a regular basis in the outpati-
ents clinic. Patients presenting with DPN or fibromyal-
gia as diagnosed by the expert physicians (i.e. fulfilling
the 1990 ACR-criteria in the case of fibromyalgia) and
at least 18 years old, were given a hand-held computer
(personal digital assistants, PDAs; Palm Tungsten E
operating on the platform OS 5.4) and requested to
complete electronic questionnaires for the epidemiologi-
cal and clinical survey. This method of data acquisition
was validated in an earlier study [19]. At intervals, PDAs
were collected and data transfer and processing were
performed under secure conditions, with anonymisation
and encryption. Physicians did not receive a financial
incentive for taking part in the study. The study proto-
col was approved by the ethical committee of the Uni-
versity of Düsseldorf and all participating patients gave
written informed consent according to the declaration
of Helsinki.
2.2. Questionnaires
In addition to standard demographic questions the fol-
lowing questionnaires were used to assess co-morbidities.
For sleep disturbances the Medical Outcomes Study
sleep scale (MOS; [20]) and for depressive disorders as
well as panic and anxiety disorders the German-language
Patient Health Questionnaire (PHQ short form; [21]) was
used. The MOS sleep questionnaire was evaluated such
as to record for each patient ‘optimal sleep’, ‘sleep distur-
bance’, ‘somnolence’, ‘sleep quantity’,a n d‘sleep ade-
quacy’. On the PHQ-9 scale scores of 0-4 indicated no
depression, of 5-9 a mild, of 10-14 a moderate, of 15-19 a
moderately severe and of 20-27 a severe depression [22].
In order to assess somatosensory symptoms and the
quality of pain perception the painDETECT question-
naire (PD-Q; [23]) was used. The latter comprises ques-
tions regarding the severity, course, quality and nature of
the patient’s pain and specific pain symptoms. The
patients were asked to describe their symptoms asso-
ciated with DPN or fibromyalgia respectively. The ques-
tions addressed the sensations in the most painful body
area: question 1 - spontaneous burning pain, question 2 -
spontaneous prickling sensations, question 3 - pain
evoked by light touch (allodynia), question 4 - sponta-
neous pain attacks, question 5 - pain evoked by thermal
stimuli, question 6 - numbness, question 7 - pain induced
by light pressure (finger), question 8 - pain radiating.
Although the painDETECT was validated in patients suf-
fering from neuropathic pain and not in fibromyalgia
patients it was used in this study, because it is an easy
assessable tool to get pain ratings and an evaluation of
sensory symptoms in a standardised way. We therefore
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tionnaire knowing that there might be false positive
scoring.
2.3. Statistics
Descriptive statistical analyses were performed with the
SAS package, version 9.2. Data for graphics were trans-
ferred to MS Excel 2003. Relations between two dichoto-
mous variables were assessed by 2’2 contingency tables,
relations between categorical data in general using k’m
contingency tables. The t-test with estimation of variances
according to Satterthwaite`s method was used to evaluate
differences in continuous variables between two groups of
patients. Continuous variables were presented within
tables by mean plus/minus standard deviation. Categorical
data were tabulated using frequencies and percentages.
In order to identify relevant subgroups of patients who
are characterized by typical symptom constellation a
hierarchical cluster analysis was performed in the entire
cohort of both aetiologies. We used the hierarchical
WARD-approach with a squared Euclidian distance
measure. As there are no objective and compelled rules
for determination of an optimal cluster number we used
3 criteria: the development of values of the WARD
fusion algorithm with respect to cluster numbers, practi-
cal decisions about minimal group numbers and deci-
sions about sense of combining groups as regards
content. To prove the evidence of the solution, a k-
means cluster, which rearranges cases for better fitting,
was performed on basis of these results. The clusters are
represented by the patterns of questionnaire scores, thus
showing the typical pathological structure of the
respecting group. Heuristic interpretations of the clus-
ters were given by experts. As this is a heuristic
approach no statistical analysis was performed. In order
to eliminate inter-individual differences of the general
perception of sensory stimuli (differences in individual
pain perception thresholds) an alternative score was
used for the cluster analysis in which the given 0-5
score of each question was subtracted by the mean of
all values marked in the 7 questions. In this individual
score values above 0 indicate a sensation which is more
intensive than the individual mean pain perception,
values below 0 indicate a sens a t i o nw h i c hi sl e s si n t e n -
sive than the individual mean pain perception.
Results
3.1. Epidemiological features and co-morbidities in DPN
and fibromyalgia
A total of 1623 patients with painful diabetic neuropathy
and 1434 fibromyalgia patients took part in the survey.
The demographic profile of the patients is shown in
Table 1. The gender ratio was even in DPN patients,
whereas in fibromyalgia patients only about 10% of the
entire cohort was male. Patients with diabetic neuropathy
were on average 10 years older and the females 4 kg hea-
vier than fibromyalgia patients. As Table 1 shows fibro-
myalgia patients had significantly higher scores in
depression and anxiety questionnaires, also sleep distur-
bances occurred more frequently in fibromyalgia patients.
3.2. Sensory symptoms in DPN and fibromyalgia
3.2.1. Pain intensity and frequency of sensory symptoms
T h ev i s u a la n a l o g u es c a l e( V A S )i n t e n s i t yv a l u e sf o r
“worst pain”, “average pain” and “current pain” were all
higher in fibromyalgia than in DPN patients (VAS level
differences ranging from 1.3 to 1.6). Seven questions of
the painDETECT questionnaire address the quality and
intensity of specific pain symptoms. The patients could
rate the perceived severity of each of these symptoms
from 0-5 (never, hardly noticed, slightly, moderately,
strongly, very strongly). In Table 2 the frequency of the
sensory disturbances that were regarded as clinically
relevant (i.e. if the patients marked a score of >3,
Table 1 Demographic and clinical characteristics
Aetiology DPN Fibromyalgia s
Patients (n,%) 1623
(100.0%)
1434 (100.0%)
Male (n,%) 824 (50.8%) 153 (10.7%) < 0.001
Female (n,%) 799 (49.2%) 1281 (89.3%)
Age (years) * 61.9 ± 13.0 51.9 ± 10.8 < 0.001
P25/P75 54/71 46/59
Height (cm) *
males 176.8 ± 7.5 176.5 ± 17.2 n.s.
females 164.2 ± 7.0 164.3 ± 8.0 n.s.
Weight (kg) *
males 90.8 ± 17.5 87.4 ± 20.9 n.s.
females 79.2 ± 16.2 74.5 ± 16.9 < 0.001
BMI (kg/m
2)*
males 29.0 ± 5.1 27.9 ± 5.8 0.023
females 29.5 ± 6.2 27.6 ± 6.0 < 0.001
PHQ-9 score, depression
None (0-4) 27.9% 7.3% < 0.001
Mild (5-9) 34.7% 27.0% < 0.001
Moderate/moderately severe
(10-19)
31.6% 51.6% < 0.001
Severe (20-27) 5.8% 14.1% < 0.001
Panic/anxiety disorder present 8.6% 17.9% < 0.001
MOS sleep scale
Sleep disturbances [0;100] * 46.7 ± 24.6 53.4 ± 24.2 < 0.001
Optimal sleep 33.2% 31.2% n.s.
Somnolence [0;100] * 46.5 ± 22.4 51.2 ± 21.5 < 0.001
Sleep quantity (hours) * 6.1 ± 1.6 5.9 ± 1.6 < 0.001
Sleep adequacy [0;100] * 49.6 ± 26.6 33.6 ± 25.4 < 0.001
*mean ± standard deviation.
BMI: body mass index; P25/P75: 25% and 75% percentiles; DPN: painful
diabetic neuropathy; n.s.: not significant.
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significant differences could be found between the enti-
ties prickling sensation (DPN 35%, FM 33%) and touch
evoked pain (DPN 18%, FM 20%). Burning pain
occurred slightly more often in DPN (33%, FM 30%),
clinically relevant pain attacks and pressure pain were
more frequently perceived by patients with fibromyalgia
(40% vs. 29%, 58% vs. 22%), whereas numbness was a
prominent descriptor in DPN (30% vs. 19%). Further-
more, the patients identified whether they experience a
“radiating” quality of their pain. This quality was used as
a descriptor in 55% of the diabetic patients and in 72%
of the fibromyalgia patients.
3.2.2. Somatosensory profiles
In addition to characteristic frequencies of each of the
sensory symptoms the patients also showed typical com-
binations of symptoms, i.e. typical sensory profiles. A
cluster analysis was performed to identify relevant sub-
groups of patients who present with a characteristic
constellation of sensory symptoms and to detect simila-
rities and differences of these profiles in both entities.
Table 3 and Figure 1 show the different clusters with
distinct symptom profiles. In the five-cluster solution we
found sensory profiles with remarkable differences in
the expression of the experienced symptoms. One sub-
group demonstrates for example a considerable thermal
sensitivity (cluster 2) whereas others show dominant
pain attacks (e.g. cluster 5). All subgroups are present in
relevant numbers (20-30% of the entire cohort). Further-
more, all of the subgroups are present in both aetiolo-
gies. However, the percentage of the two different pain
syndromes in the different clusters varied considerably
and some of the clusters seem to be relatively aetiology-
specific. Subgroup 1 and 2 occur in relevant numbers
(25-26%) in patients with fibromyalgia whereas they are
rare in patients with DPN (10-11%). According to the
musculoskeletal nature of fibromyalgia pain these
groups are characterized by relevant pressure induced
pain. In contrast subgroup 4 is relatively specific for
DPN (29% of cases vs. 9% in fibromyalgia). This cluster
is characterized by relevant numbness and the lack of
allodynia, pain attacks and thermally induced pain. Sub-
group 3 is the cluster in which the distribution of cases
is most equal. The patients in this cluster seem to suffer
most from burning pain and pressure pain. Subgroup 5
is closely related with subgroup 1, with the difference
that this cluster is only dominated by pain attacks and
not by pressure pain. Astonishingly, taken into account
that tenderness is one of the main diagnostic criteria of
FM, 19% of fibromyalgia patients belong to this cluster.
Discussion
4.1. Epidemiological data and co-morbidities
In accordance with other epidemiological studies the
female male ratio in fibromyalgia was found to be 10:1.
In patients with DPN the distribution between male and
female patients is equivalent. Depressive symptoms and
anxiety were significantly more often present in fibro-
myalgia than in DPN which reflects the results of earlier
studies [6]. Sleep disturbances were mentioned more
frequently in patients with fibromyalgia, they also per-
ceive their sleep as less adequate. This is in line with
the finding that sleep disturbances are generally
regarded as a major co-morbidity associated with fibro-
myalgia [24].
4.2. Similarities and differences of sensory symptoms
It is important to estimate which sensory symptoms are
clinically relevant as perceived by the patients them-
selves. Therefore, ‘Patient-Reported Outcomes’ (PROs)
that collect health-related data directly from the patients
are increasingly used in clinical research [18]. Sensory
disturbances were considered as clinically relevant if the
patients replied to the questions with a score of >3
Table 2 Pain and sensory symptoms in DPN (n = 1623)
and fibromyalgia patients (n = 1434)
Aetiology DPN Fibromyalgia s
VAS worst pain * 6.4 ± 2.6 8.0 ± 1.7 < 0.001
VAS average pain * 5.0 ± 2.3 6.3 ± 1.9 < 0.001
VAS current pain * 4.6 ± 2.5 5.9 ± 2.2 < 0.001
Q1-7: Clinical relevant complaint
(score >3)
Q1, burning 33% 30% 0.018
Q2, prickling 35% 33% n.s.
Q3, allodynia 18% 20% n.s.
Q4, attacks 29% 40% < 0.001
Q5, thermal 14% 26% < 0.001
Q6, numbness 30% 19% < 0.001
Q7, pressure 22% 58% < 0.001
Radiating pain 54.7% 72.0% < 0.001
* mean ± standard deviation.
DPN: painful diabetic neuropathy; VAS: visual analogue scale from 0 to 10;
Q1-7: Question 1 to 7 of PD-Q.
Table 3 Subgroups of patients with different sensory
profiles
Subgroup (n) Fibromyalgia n (%) DPN n (%)
Cluster 1 (525) 367 (25.6) 158 (9.7)
Cluster 2 (532) 352 (24.6) 180 (11.1)
Cluster 3 (584) 317 (22.1) 267 (16.5)
Cluster 4 (588) 123 (8.6) 465 (28.7)
Cluster 5 (828) 275 (19.2) 553 (34.1)
Total 1434 1623
DPN patients (n = 1623) and fibromyalgia patients (n = 1434).
DPN: painful diabetic neuropathy.
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Figure 1 Subgroups of patients based on sensory symptoms. To identify relevant subgroups of patients with a characteristic symptom
profile a hierarchical cluster analysis was performed in patients with painful diabetic neuropathy and fibromyalgia. Each cluster is represented by
the patterns of questionnaire scores (adjusted individual mean) thus showing the typical pathological structure of the respecting group. By using
this approach five clusters with distinct symptom profiles could be detected. Sensory profiles show remarkable differences in the expression of
the symptoms. % : frequency of occurrence, DPN : painful diabetic neuropathy, FM : fibromyalgia.
Koroschetz et al. BMC Neurology 2011, 11:55
http://www.biomedcentral.com/1471-2377/11/55
Page 5 of 8(strongly, very strongly) (Table 2). Interestingly, patients
of both aetiologies chose very similar descriptors to
characterize their sensory perceptions. In fact, pain of
burning quality, a prickling sensation and the existence
of touch-evoked allodynia was indicated in almost the
same frequencies. Thus, both disease entities are
obviously associated with the perception of similar sen-
sory symptoms. It has to be kept in mind, however, that
the patients might not perceive exactly the same sensory
phenomenon although they mark the same verbal
description.
Prickling or ant-crawling sensations are well-known
features of polyneuropathies. In these disorders the
patients perceive their discomfort in both the skin and
deeper structures mainly in the feet or hands. The simi-
lar high frequency of severe prickling sensations in
fibromyalgia patients is intriguing. In contrast to DPN,
patients with fibromyalgia locate the prickling mostly
into deeper tissues in particular in the muscles. The
pathophysiological mechanisms underlying prickling in
fibromyalgia might, nonetheless, be similar to that in
DPN. Ectopic activity in non-nociceptive afferents from
deep somatic tissues potentially induced by relative
muscle ischemia might be a potential option. Muscle
ischemia was described repeatedly in fibromyalgia
[25-27] and it is thought that continuous ischemia in
muscles has a high potential to lead to peripheral sensi-
tization and to ectopic firing of non-nociceptive as well
as nociceptive afferent neurons [28].
Another unexpected finding is the relatively high inci-
dence of touch-evoked allodynia in fibromyalgia (20%).
Allodynia is thought to be induced by activation of
touch-sensitive cutaneous Ab-fibers that synapse on
nociceptive second-order neurons in the CNS. Thus,
allodynia might be explained by a convergent afferent
input of deep somatic and skin nerves on sensitized sec-
ond-order neurons [29].
Severe painful attacks were significantly more often
described in fibromyalgia than in DPN (40% vs. 29%).
The precise meaning of this sensory perception, how-
ever, very likely differs in both aetiologies. Patients with
DPN experience the classical neuropathic shooting pain
which occurs spontaneously for seconds, comparable to
the attacks in trigeminal neuralgia. In contrast, if fibro-
myalgia patients use the descriptor “pain attacks” from
our clinical experience they state that even the slightest
movement of the affected musculature is capable of
inducing a very severe, short lasting pain which ceases
immediately after seconds.
Thermal sensitivity within the painful area occurs
nearly twice as often in fibromyalgia than in DPN (26%
vs. 14%). Unfortunately, this question was not designed
to differentiate between heat and cold sensitivity. Clini-
cal experience indicates that DPN patients frequently
suffer from heat hyperalgesia which is thought to be a
characteristic symptom of hyperactive and sensitized
cutaneous nociceptors. On the contrary, fibromyalgia
patients frequently describe that their pain is enhanced
when in contact with cold environmental temperature.
This experience is in line with other studies which have
found a high prevalence of cold hyperalgesia in fibro-
myalgia patients [13,15]. It is very likely that a central
phenomenon eventually involving the sympathetic ner-
vous system might underlie the cold sensitivity in fibro-
myalgia rather than alterations in peripheral nociceptive
neurons.
Numbness is a descriptor for sensory deafferentiation
of the skin. It is the only symptom which is described
significantly more often in DPN than in fibromyalgia
(30% vs. 19%). It reflects the clinical observation of a
length-dependent denervation of hands and feet which
occurs in DPN patients. Nevertheless finding numbness
also in one fifth of the fibromyalgia patients may be a
hint for large fibre dysfunction in a subgroup of this
cohort [7].
Pressure induced pain, i.e. deep somatic hyperalgesia,
is thought to be characteristic for fibromyalgia, as is
reflected in the ACR-criteria. Hyperactive nociceptive
processing from sensitized nociceptors innervating deep
somatic tissues is likely involved. Assessing tenderness
in this study was not standardized (e.g. with pressure
dolorimeter devices or more elaborate psychophysical
methods). For evaluating tender points in fibromyalgia
patients examiners applied either pressure dolorimeter
devices or digital palpation. Subjectively 58% of the
fibromyalgia patients described the pain intensity to
slight pressure as strong or very strong but only 22% of
the DPN patients experienced a slight pressure in the
affected area as painful. Interestingly, 42% of the fibro-
myalgia patients did not mark pressure pain as clinically
relevant, although all of the included patients fulfilled
the ACR-criteria. This finding clearly shows that pres-
sure pain is only one part of the entire clinical picture
of fibromyalgia and that for a subset of patients, pres-
sure pain obviously is not the most disabling symptom.
4.3. Sensory profiles in DPN and fibromyalgia
We performed a cluster analysis to identify relevant sub-
groups of patients who demonstrate characteristic sen-
sory profiles (Table 3, Figure 1). This analysis revealed 2
subgroups that are characteristic for fibromyalgia (sub-
group 1, 2) and one (subgroup 4) that occurs predomi-
nantly in DPN. For the subgroups 3 and 5 a
considerable overlap could be identified. Subgroup 3
was detected in 22% of fibromyalgia and 17% of DPN
patients. The dominant symptoms of this subgroup are
pain attacks in combination with burning and prickling
pain whereas thermal sensitivity and numbness are rare.
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ities. These patients perceive most symptoms in a simi-
lar frequency and intensity, only pain attacks are slightly
more dominant. This profile occurs in 19% of fibromyal-
gia patients and in 34% of DPN patients.
It is likely that sensory perceptions and profiles trans-
late into distinct pathophysiological mechanisms. Since
many of the sensory profiles are typical either for DPN
or fibromyalgia the combination of different pathophy-
siological mechanisms is likely to be relatively aetiology-
specific. However, 20-35% of patients show sensory pat-
terns which can be found in both entities. Thus, in
these subgroups there might also be an overlap of
pathophysiological mechanisms.
Up to the present in the majority of fibromyalgia
patients there are no nerve lesions demonstrable. How-
ever, it was repeatedly hypothesized that changes in the
milieu of muscles and other deep somatic structures
(for example induced by ischemia) might lead to a sensi-
tization of peripheral nociceptors that innervate deep
somatic structures and as a consequence generate and
maintain pain in fibromyalgia patients [5]. It might be
that these processes have the potential to induce a simi-
lar state of hyperactivity in nociceptive neurons as
observed after nerve damage. The pathological sensitiza-
tion of nociceptive afferents innervating deep somatic
structures might drive secondary processes in the cen-
tral nervous system, i.e. lead to central sensitization.
Alternatively, sensitization of spinal cord nociceptive
neurons might be initiated and maintained by a loss of
descending inhibitory control. A dysfunction in pain
inhibition has been proposed to be one of the factors
which could lead to a disposition to develop fibromyal-
gia [30]. If this is the case, the characteristic sensory
profile found in both disease entities could be induced
without any peripheral trigger.
4.4 Limitations of the study
The multi-center, cross sectional design of the study
represents just a short time frame and allows no conclu-
sion on dynamics or cause and effect of symptoms. The
approach of this study was to gather reliable information
regarding the incidence of sensory symptoms, which are
frequently complained aboutb yf i b r o m y a l g i ap a t i e n t s
and to compare these data with the data of patients suf-
fering from DPN in a large cohort of patients. The pain-
DETECT questionnaire was not validated in
fibromyalgia patients. Originally it was validated to pre-
dict the probability of a neuropathic pain component in
a cohort of patients suffering from typical neuropathic
entities (e.g. PHN, PNP) or nociceptive pain (e.g.
osteoarthritis, inflammatory arthropathies). The fact that
also fibromyalgia patients score positive in the painDE-
TECT questionnaire reflects that this patient group
suffers from symptoms that can not be categorized as
nociceptive pain. Nevertheless fibromyalgia can not be
viewed as a neuropathic pain state, which is in accor-
dance with the new definition of neuropathic pain. But
i tm i g h tb et h a tc o m p a r a b l e mechanisms like central
sensitization processes in both patient groups lead to
similarities in symptomatology and therefore in parallels
of answering symptom-based questionnaires.
The answers of self-report questionnaires may be
biased by the patients’ personal feelings and health state
at the time of filling out the questionnaires (exaggera-
tion vs. understatement), by missing responses as well as
giving consideration to the researchers and social expec-
tations. This limitation is relevant for all studies which
are based on self-report questionnaires. Nevertheless
these studies are desperately needed in order to be able
to design treatment strategies which target the symp-
toms reported by patients. Results of self-report ques-
tionnaires should be compared with more objective
measurements like e.g. standardised sensory testing,
functional imaging and laser or heat evoked potentials.
Psychological factors like hypervigilance or catastrophiz-
ing were not evaluated in this study and may have had
an impact on the results. Interpretation of underlying
mechanisms in fibromyalgia according to reported sen-
sory symptoms is speculative but is the basis for creat-
ing further studies to proof possible concepts.
Conclusions
The results of this study indicate that patients can be
classified on the basis of their sensory symptoms by the
use of patient reported questionnaires. The study shows
that DPN and fibromyalgia patients experience very
similar sensory phenomena. The combination of sensory
symptoms - the sensory profile - is in most cases dis-
tinct and almost unique for each one of the two entities
indicating aetiology-specific mechanisms of symptom
generation. The overlap of sensory profiles which can be
found in 20-35% of patients in both aetiologies might be
associated with similar mechanisms operating in certain
subgroups of DPN and fibromyalgia patients. This ques-
tionnaire based approach will be an opportunity to clo-
sely monitor our pain patients regarding their sensory
symptoms and pain ratings and opens the possibility to
focus on treatment strategies for the symptoms the
patients suffer from most.
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